The TyG index is significantly associated with NAFLD and shows superior ability for identify NAFLD risk compared with other lipid and glycemic parameters in T2DM (BMC Endocrine Disorders)
Diabetes News
Tag: NAFLD
Risk Factors for Nonalcoholic Fatty Liver Disease in Postmenopausal Women with Type 2 Diabetes Mellitus and the Correlation with Bone Mineral Density at Different Locations
Complicated NAFLD in postmenopausal women with T2DM is associated with weight gain, poor blood glucose control, abnormal lipid metabolism, and elevated UA levels. In addition, the NAFLD group had higher femoral neck and total hip BMD than the non-NAFLD group, suggesting NAFLD in postmenopausal women with T2DM may reduce the risk of osteoporosis (Metabolic Syndrome and Obesity)
An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care
From the perspectives of health practitioners, there is a gap in clinical practice for the implementation of clear, evidence-based guidelines for NAFLD in people with T2D. By focusing on comorbidity prevention and integrating NAFLD as a diabetes complication to be addressed during established cycles of care, many barriers to implementing a NAFLD pathway in primary care could be overcome (Diabetic Medicine)
The Association Between Vitamin D and Type 2 Diabetes Mellitus Complicated with Non-Alcoholic Fatty Liver Disease: An Observational Cross-Sectional Study
This study suggests that T2DM people with BMI > 23kg/m2 were more susceptible to NAFLD by vitamin D deficiency and that it is necessary to maintain optimal serum vitamin D levels in this population (Metabolic Syndrome and Obesity)
Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials
Treatment with SGLT2 inhibitors improves liver structure and function in patients with T2D. This meta-analysis suggests that SGLT2 inhibitors are a promising pharmacological approach for treatment of NAFLD (Diabetes/Metabolism Research and Reviews)
Effects of SGL2 inhibitors on liver parameters and steatosis: a meta‐analysis of randomized clinical trials
Treatment with SGLT2 inhibitors improves liver structure and function in patients with type 2 diabetes. This meta‐analysis suggests that SGLT2 inhibitors are a promising pharmacological approach to NAFLD (Diabetes/Metabolism Research and Reviews)
Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis
NAFLD prevalence in patients with type 1 diabetes is considerable and is highly dependent on the specific diagnostic modality and NAFLD definition used. These data are helpful in directing actions to standardize NAFLD diagnosis, which will help defining contributing mechanisms and outcomes (Journal of Clinical Endocrinology & Metabolism)
Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes
Diagnosis of NAFLD with or without elevated serum liver enzymes was inversely correlated with certain chronic diabetes microvascular complications (Primary Care Diabetes)
Diabetes Mellitus, Nonalcoholic Fatty Liver Disease, and Conjugated Linoleic Acid (Omega 6): What Is the Link?
Insulin resistance is the main link between NAFLD, diabetes, and obesity. Conjugated linoleic acid (CLA) has a role in fat deposition in the liver and in development and improvement of insulin resistance. Fatty food had a documented role in the pathogenesis of obesity and diabetes but it can also be the cure (Journal of Diabetes Research)
Association of grade of non-alcoholic fatty liver disease and glycated albumin to glycated hemoglobin ratio in patients with type 2 diabetes mellitus
The present study showed that GA/HbA1c ratio was significantly associated with the presence and severity of NAFLD on US (Diabetes Research and Clinical Practice)
Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes
Increased UUAE levels were significantly associated with the presence of NAFLD and increase of ALT in T2DM. UUAE may be a clinically significant measure in assessing the risk of NAFLD in T2DM (Journal of Diabetes and Its Complications)
The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes
Fatty Liver Index assessed nonalcoholic fatty liver disease (FLI-NAFLD) was present in the majority of T2DM patients of our sample and metabolic derangement, not alcohol consumption, was mainly associated with the disease. FLI-NAFLD patients have a worse metabolic profile (Journal of Diabetes Research)
Assessment of the relation between non-alcoholic fatty liver disease and diabetic complications
NAFLD combined with type 2 diabetes is associated with the presence of significant coronary artery disease and hypertension (Journal of Diabetes Investigation)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Liraglutide was safe, well tolerated, and led to histological resolution of non-alcoholic steatohepatitis, warranting extensive, longer-term studies (The Lancet)
Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus
NAFLD might be a risk factor for DN. Elevated liver fat content could be associated with higher DN burden (PLoS ONE)
Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE
This proof-of-concept study demonstrates that T2DM has significant rates of both NAFLD and advanced fibrosis. Concomitant screening for NAFLD and advanced fibrosis by using MRI-proton density fat fraction and magnetic resonance elastography in T2DM is feasible and may be considered after validation in a larger cohort (Alimentary Pharmacology & Therapeutics)
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms
It is mainly adipose tissue insulin resistance that results in increased hepatic de novo lipogenesis, inflammation, and lipotoxicity. Although genetics predispose to NAFLD, an unhealthy lifestyle, including high-fat/high-sugar diets and low physical activity, increases the risk. In addition, alterations in gut microbiota and environmental chemical agents, acting as endocrine disruptors, may play a role (Current Diabetes Reports)
Glycosmedia is also available as an App: